Overview

Gender

male

Axel Bolte is a member of Kolltan's Board of Directors.

Axel Bolte has over ten years' experience in healthcare venture capital and serves as an Investment Advisor to HBM Partners Ltd.

Previously, Axel Bolte was an investment manager at NMT New Medical Technologies AG, the first dedicated Swiss healthcare venture capital firm. Prior to his career in the financial sector, Axel Bolte held various research and development positions at Serono S.A. Axel Bolte has served on a number of boards, including PTC Therapeutics, Inc., Lux Biosciences, Inc., Ophthotech Corp., MPex Pharmaceuticals, Inc., Nabriva Therapeutics AG, Newron Pharmaceuticals S.p.A. and others.

He earned his M.Sc. in biochemistry from the Swiss Federal Institute of Technology in Zurich and the University of Cambridge, UK, and his M.B.A. degree from the University of St. Gallen in Switzerland.